Adaptive Biotechnologies Corp (ADPT) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Adaptive Biotechnologies is a commercial-stage company advancing immune medicine through its Minimal Residual Disease (MRD) and Immune Medicine business areas. The company's primary commercial product is the clonoSEQ test for detecting MRD in lymphoid cancers. A significant event during the period was the termination of the company's worldwide collaboration agreement with Genentech, Inc., effective February 9, 2026.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $93.97 million | $46.44 million | $205.30 million | $131.50 million |
| Net Income (Loss) | $9.55 million | ($32.10 million) | ($45.88 million) | ($125.88 million) |
| Diluted EPS | $0.06 | ($0.22) | ($0.30) | ($0.86) |
| Operating Margin | 11.0% | (70.3%) | (21.6%) | (97.9%) |
| Cash & Marketable Securities | $216.8 million (as of Sept 30, 2025) | |||
| Revenue Interest Liability | $131.84 million (net) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 102% year-over-year in Q3 2025. This was driven by a 52% increase in MRD revenue (due to higher clonoSEQ test volume and regulatory milestones) and a 315% increase in Immune Medicine revenue.
- Genentech Termination Impact: The termination of the Genentech Agreement resulted in the recognition of $33.7 million in deferred revenue during Q3 2025. While this boosted current revenue, the company is no longer eligible for future milestones or royalties from this deal.
- Profitability: The company reported a net income of $9.5 million for Q3 2025, a significant turnaround from the $32.1 million net loss in Q3 2024. This was the first profitable quarter since inception.
- Expense Management: Research and Development expenses decreased slightly ($0.5 million) year-over-year in Q3, while Sales and Marketing expenses increased by $2.9 million to support commercialization.
- Impairment Charges: Unlike the prior year, there were no impairment charges for long-lived assets in Q3 2025. In Q3 2024, the company recorded $7.2 million in impairment charges related to restructuring.
Guidance, Outlook, and Risks
- Outlook: Management expects MRD revenue to increase long-term due to expanded Medicare coverage and new indications. Conversely, Immune Medicine revenue is expected to decrease in the short term following the Genentech termination, relying more on service revenue from biopharmaceutical customers.
- Liquidity: The company holds $216.8 million in cash and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months. The company has a Revenue Interest Purchase Agreement with OrbiMed, under which it may request up to an additional $125 million in installments (subject to conditions).
- Risks:
- Collaboration Loss: The winding down of the Genentech agreement creates uncertainty regarding future Immune Medicine revenue streams and potential loss of innovation leverage.
- Reimbursement: Revenue is heavily dependent on Medicare and commercial payor reimbursement rates for the clonoSEQ test.
- Regulatory Milestones: A portion of MRD revenue is tied to third-party regulatory approvals, which are outside the company's control.
- Unusual Items: The $33.7 million revenue recognition from the Genentech contract modification is a non-recurring item that significantly altered the Q3 financial profile.
Investor Verification Checklist
- Verify the sustainability of MRD revenue growth independent of the one-time Genentech revenue recognition.
- Confirm the timeline and conditions for the remaining $125 million available under the OrbiMed Revenue Interest Purchase Agreement.
- Monitor the impact of the Genentech termination on future Immune Medicine R&D pipeline and potential new collaborations.
- Review the details of the new Medicare coverage expansion for Mantle Cell Lymphoma (MCL) and its effect on test volume.
- Assess the company's burn rate and runway given the shift from a loss to a profit in Q3, ensuring the profit is not solely due to non-recurring revenue adjustments.